A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial

Nonalcoholic steatohepatitis (NASH) is a multifactorial disease involving different contributing mechanisms, with no approved therapies so far. Tropifexor (TXR), a farnesoid X receptor agonist, and cenicriviroc (CVC), a chemokine receptor types 2/5 antagonist, target the steatotic, inflammatory, and/or fibrotic pathways involved in NASH.

Source: Contemporary Clinical Trials - November 11, 2019 Category: Radiology Authors: Marcos Pedrosa, Star Seyedkazemi, Sven Francque, Arun Sanyal, Mary Rinella, Michael Charlton, Rohit Loomba, Vlad Ratziu, Jossy Kochuparampil, Laurent Fischer, Sujata Vaidyanathan, Quentin M. Anstee Source Type: research